Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.37 |
| ▸ | FNTB | P49356 | 11/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220418 | 0.86 | ALDH1A1 (0.40) | FNTAFNTBPGGT1BLMNAALDH1A1 | |
| SCHEMBL7754941 | 0.74 | TRPV4 (0.39) | FNTAFNTBPGGT1BLMNAALDH1A1 | |
| SCHEMBL7754946 | 0.74 | L3MBTL1 (0.40) | FNTAFNTBPGGT1BMEP1BL3MBTL1 | |
| SCHEMBL7236823 | 0.72 | FNTA (0.42) | FNTAFNTBPGGT1B | |
| SCHEMBL7698892 | 0.71 | MAPT (0.42) | FNTAFNTBPGGT1BLMNAALDH1A1 | |
| SCHEMBL6003410 | 0.71 | MAPT (0.42) | FNTAFNTBPGGT1BLMNAALDH1A1 | |
| SCHEMBL7227924 | 0.70 | TRPV4 (0.34) | FNTAFNTBPGGT1BTRPV4 | |
| SCHEMBL7681015 | 0.69 | L3MBTL1 (0.39) | ALDH1A1MEP1BL3MBTL1TRPV4 | |
| SCHEMBL7228470 | 0.68 | TRPV4 (0.35) | FNTAFNTBPGGT1BTRPV4 | |
| SCHEMBL7222558 | 0.68 | S1PR3 (0.37) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6525074-B2 | Peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020049217-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2001051126-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049217-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | FNTA 1/4885FNTB 5/4885PGGT1B 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.